The earnings call was generally positive, highlighting significant cost reductions, strong cash reserves, and revenue growth in key segments. However, there were concerns related to biosecurity revenue guidance and challenges in the leasing market, which were noted as potential risks.

Company Guidance

In the recent call, Ginkgo Bioworks provided detailed guidance on their financial and strategic progress for the second quarter of 2025. The company reported achieving a $250 million annual run rate cost savings a quarter early, contributing to an improved cash position of $474 million in cash and equivalents, with no bank debt. Ginkgo's Cell Engineering business generated $39 million in revenue, marking an 8% increase from the same period in 2024, while the Biosecurity segment brought in $10 million with an 18% gross margin. Overall, adjusted EBITDA improved to a negative $28 million from a negative $99 million year-over-year, a 72% improvement. The company reiterated its 2025 revenue guidance of $167 million to $187 million, with a focus on achieving adjusted EBITDA breakeven by the end of 2026. Ginkgo emphasized its strategic shift towards the life science tools market, detailing innovations in automation, data services, and the launch of a new reagent product, all aimed at driving growth and profitability.

Cost Reduction Achievements

Ginkgo achieved a $250 million annual run rate cost savings target a quarter early, significantly reducing their cash burn.

Cash Reserve and Debt Position

The company reported $474 million in cash and cash equivalents with no bank debt, providing a strong cash margin of safety.

Revenue Growth in Cell Engineering

Cell Engineering revenue grew to $39 million, an 8% increase compared to the second quarter of 2024.

Improvement in Adjusted EBITDA

Adjusted EBITDA improved by 72%, from negative $99 million in Q2 2024 to negative $28 million in Q2 2025.

Expansion into Life Science Tools

Successfully launched a new reagent product with initial sales and over 100 sample requests, marking an entry into the academic research market.

Ginkgo Bioworks Holdings (DNA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DNA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-1.24 / -	-1.08	―	―	―
Aug 07, 2025	2025 (Q2)	-1.57 / -1.10	-4.4	75.00% (+3.30)
May 06, 2025	2025 (Q1)	-1.53 / -1.68	-3.2	47.50% (+1.52)
Feb 25, 2025	2024 (Q4)	-1.50 / -2.00	-4.4	54.55% (+2.40)
Nov 12, 2024	2024 (Q3)	-2.73 / -1.08	-6.4	83.13% (+5.32)
Aug 08, 2024	2024 (Q2)	-3.10 / -4.40	-3.6	-22.22% (-0.80)
May 09, 2024	2024 (Q1)	-3.33 / -3.20	-4.4	27.27% (+1.20)
Feb 29, 2024	2023 (Q4)	-3.87 / -4.40	-4	-10.00% (-0.40)
Nov 08, 2023	2023 (Q3)	-3.66 / -6.40	-16.4	60.98% (+10.00)
Aug 09, 2023	2023 (Q2)	-3.45 / -3.60	-16.4	78.05% (+12.80)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DNA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$13.46	$12.29	-8.69%
May 06, 2025	$6.45	$7.40	+14.73%
Feb 25, 2025	$10.29	$9.11	-11.47%
Nov 12, 2024	$8.39	$8.60	+2.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.